iData Insights

Traumatic Brain Injury - Pipeline Review, H2 2015 Now Available at iData Insights

Press Release   •   Dec 01, 2015 16:32 IST

Traumatic Brain Injury - Pipeline Review, H2 2015 Summary Global Markets Direct s, Traumatic Brain Injury - Pipeline Review, H2 2015, provides an overview of the Traumatic Brain Injurys therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Traumatic Brain Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Traumatic Brain Injury and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Traumatic Brain Injury - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Traumatic Brain Injury and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Traumatic Brain Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Traumatic Brain Injury pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Traumatic Brain Injury - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Traumatic Brain Injury pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Browse Complete Report with TOC @

To Get Sample Copy of Report visit @

Table of Contents

Table of Contents

2 List of Tables

6 List of Figures

7 Introduction

8 Global Markets Direct Report Coverage

8 Traumatic Brain Injury Overview

9 Therapeutics Development

10 Pipeline Products for Traumatic Brain Injury - Overview

10 Pipeline Products for Traumatic Brain Injury - Comparative Analysis

11 Traumatic Brain Injury - Therapeutics under Development by Companies

12 Traumatic Brain Injury - Therapeutics under Investigation by Universities/Institutes

17 Traumatic Brain Injury - Pipeline Products Glance 18 Late Stage Products

18 Clinical Stage Products

19 Early Stage Products

20 Unknown Stage Products

21 Traumatic Brain Injury - Products under Development by Companies

22 Traumatic Brain Injury - Products under Investigation by Universities/Institutes

27 Traumatic Brain Injury - Companies Involved in Therapeutics Development

28 Adamas Pharmaceuticals, Inc.

28 ALSP, Inc.

29 Amarantus Bioscience Holdings, Inc.

30 Athersys, Inc.

31 BHR Pharma, LLC

32 Cognosci, Inc.

33 Euroscreen S.A.

34 Grupo Ferrer Internacional, S.A.

35 International Stem Cell Corporation 36 Io Therapeutics, Inc.

37 Ischemix

38 Karyopharm Therapeutics, Inc.

39 Kyorin Pharmaceutical Co., Ltd.

40 Levolta Pharmaceuticals, Inc.

41 Lixte Biotechnology Holdings, Inc.

42 Lpath, Inc. 43 MandalMed, Inc.

44 Mapreg S.A.S.

45 Mnemosyne Pharmaceuticals, Inc.

46 Neuralstem, Inc.

47 Neuren Pharmaceuticals Limited 48 NeuroHealing Pharmaceuticals Inc.

49 NeuroNascent, Inc.

50 Neuronax SAS

51 NeuroVive Pharmaceutical AB

52 Omeros Corporation

53 PharmatrophiX, Inc.

54 Phylogica Limited

55 Prevacus, Inc.

56 PsychoGenics, Inc.

57 QR Pharma, Inc.

58 RAPID Pharmaceuticals AG

59 RegeneRx Biopharmaceuticals, Inc.

60 Remedy Pharmaceuticals, Inc.

61 Sage Therapeutics 62 SanBio, Inc.

63 STATegics, Inc.

64 Tetra Discovery Partners LLC

65 VG Life Sciences, Inc.

66 Traumatic Brain Injury - Therapeutics Assessment

67 Assessment by Monotherapy Products

67 Assessment by Combination Products

68 Assessment by Target 69 Assessment by Mechanism of Action

72 Assessment by Route of Administration

75 Assessment by Molecule Type

77 Drug Profiles 79 2-DG - Drug Profile

79 ALP-496 - Drug Profile 81 amantadine hydrochloride ER - Drug Profile

83 AMRS-001 - Drug Profile

85 apomorphine hydrochloride - Drug Profile

88 AST-002 - Drug Profile

90 AVL-8168 - Drug Profile

91 Cell Therapy to Activate hNT-3 for Spinal Cord and Traumatic Brain Injury - Drug Profile

92 CHEC-7 - Drug Profile 94 CHEC-9 - Drug Profile

95 CMX-2043 - Drug Profile 97 CNB-001 - Drug Profile

99 COG-1410 - Drug Profile

101 cyclosporine - Drug Profile

103 dexamethasone acetate + melatonin - Drug Profile

107 EPO-Variant - Drug Profile

108 ESN-502 - Drug Profile

109 felbamate - Drug Profile

110 FIB-117 - Drug Profile

111 glyburide - Drug Profile

112 HBI-002 - Drug Profile

114 HBI-137 - Drug Profile

115 HBN-1 - Drug Profile

116 HBN-2 - Drug Profile

117 HPI-201 - Drug Profile

118 ibudilast - Drug Profile

120 ICCN-100 - Drug Profile

122 IRX-4204 - Drug Profile

123 ISC-hpNSC - Drug Profile

125 JM-4 - Drug Profile

127 KPT-350 - Drug Profile

128 LB-201 - Drug Profile

129 LB-205 - Drug Profile

130 LM11A-31 - Drug Profile

131 Lpathomab - Drug Profile

132 MAP-4343 - Drug Profile

134 MultiStem - Drug Profile

135 ND-478 - Drug Profile

139 NNI-370 - Drug Profile

140 NNZ-2591 - Drug Profile

141 NSI-189 - Drug Profile

142 NSI-566 - Drug Profile

144 NVP-019 - Drug Profile

146 NVX-428 - Drug Profile

147 NX-210 - Drug Profile

148 PGI-02776 - Drug Profile

149 Posiphen - Drug Profile

151 progesterone - Drug Profile

153 PRV-002 - Drug Profile

154 PYC-35 - Drug Profile

155 PYC-36 - Drug Profile

156 PYC-38 - Drug Profile

157 PYC-98 - Drug Profile

158 R-503 - Drug Profile

159 RAP-701 - Drug Profile

161 RGN-352 - Drug Profile

162 SB-623 - Drug Profile

164 sepranolone - Drug Profile

166 Small Molecule to Activate Epsilon PKC for Traumatic Brain Injury - Drug Profile

169 Small Molecule to Antagonize GPR17 for Central Nervous System Disorders - Drug Profile

170 Small Molecule to Inhibit Amyloid Beta Peptide for Traumatic Brain Injury and Alzheimer s Disease - Drug Profile

171 Small Molecules for Stroke and Traumatic Brain Injury - Drug Profile

172 Small Molecules to Activate P2Y Receptor for Stroke and Traumatic Brain Injury - Drug Profile

173 Small Molecules to Agonize TrkB for Ophthalmology and Central Nervous System - Drug Profile

174 Small Molecules to Antagonize NMDA2A for Central Nervous System Disorders - Drug Profile

175 Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile

176 Small Molecules to Inhibit PBR for Traumatic Brain Injury and Neurodegenerative Diseases - Drug Profile

177 Stem Cell Therapy for CNS Disorders - Drug Profile

178 STSE-15 - Drug Profile

179 T-094 - Drug Profile

180 TBI-121 - Drug Profile

181 TBI-122 - Drug Profile

182 TBI-123 - Drug Profile

183 trofinetide - Drug Profile

184 UH-0113 - Drug Profile

186 UH-0213 - Drug Profile

187 VG-1177 - Drug Profile

188 VitalHeme - Drug Profile

190 VOLT-02 - Drug Profile

192 Traumatic Brain Injury - Recent Pipeline Updates

193 Traumatic Brain Injury - Dormant Projects

250 Traumatic Brain Injury - Discontinued Products

253 Traumatic Brain Injury - Product Development Milestones

254 Featured News & Press Releases 2

54 Appendix

260 Methodology 260 Coverage

260 Secondary Research

260 Primary Research

260 Expert Panel Validation

260 Contact Us

260 Disclaimer

Read More

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

Contact Us:
iData Insights

Tel: 1-866-237-2965


AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects.